These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38282037)
1. Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study. Gao L; Yang L; Zhou S; Zhu W; Han Y; Chen S; Xue S; Wang Y; Qiu H; Wu D; Wu X Stem Cell Res Ther; 2024 Jan; 15(1):24. PubMed ID: 38282037 [TBL] [Abstract][Full Text] [Related]
2. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. Guru Murthy GS; Kim S; Hu ZH; Estrada-Merly N; Abid MB; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bredeson C; Cahn JY; Cerny J; Diaz Perez MA; Farhadfar N; Gale RP; Ganguly S; Gergis U; Hildebrandt GC; Grunwald MR; Hashmi S; Hossain NM; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Hamilton BK; Lazarus HM; Liesveld J; Litzow M; Marks DI; Murthy HS; Nathan S; Nazha A; Nishihori T; Patel SS; Pawarode A; Rizzieri D; Savani B; Seo S; Solh M; Ustun C; van der Poel M; Verdonck LF; Vij R; Wirk B; Oran B; Nakamura R; Scott B; Saber W JAMA Oncol; 2022 Mar; 8(3):404-411. PubMed ID: 35024768 [TBL] [Abstract][Full Text] [Related]
3. Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single-center retrospective study. Huang J; Huang F; Fan Z; Xu N; Xuan L; Liu H; Shi P; Jiang L; Zhang Y; Sun J; Liu Q Cancer Med; 2020 Sep; 9(17):6244-6255. PubMed ID: 32686915 [TBL] [Abstract][Full Text] [Related]
4. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study. Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196 [TBL] [Abstract][Full Text] [Related]
5. Choosing Between Older Matched Sibling Donor and Younger Matched Unrelated Donor in Allogeneic Hematopoietic Cell Transplantation: Comparison of Clinical Outcomes in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Pereira MP; Remberger M; Chen C; Gerbitz A; Kim DDH; Kumar R; Lam W; Law AD; Lipton JH; Michelis FV; Novitzky-Basso I; Viswabandya A; Mattsson J; Pasic I Transplant Cell Ther; 2023 Nov; 29(11):697.e1-697.e10. PubMed ID: 37579919 [TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985 [TBL] [Abstract][Full Text] [Related]
7. Peritransplantation Glucocorticoid Haploidentical Stem Cell Transplantation Is a Promising Strategy for AML Patients With High Leukemic Burden: Comparison With Transplantations Using Other Donor Types. Kaida K; Ikegame K; Inoue T; Maruyama S; Ishii S; Uchida N; Doki N; Eto T; Fukuda T; Katayama Y; Takada S; Kawakita T; Ichinohe T; Atsuta Y; Daimon T; Ogawa H Transplant Cell Ther; 2023 Apr; 29(4):273.e1-273.e9. PubMed ID: 36641032 [TBL] [Abstract][Full Text] [Related]
8. [Comparison of umbilical cord blood transplantation and hematopoietic stem cell transplantation from HLA-matched sibling donors in the treatment of myelodysplastic syndrome-EB or acute myeloid leukemia with myelodysplasia-related changes]. Zhu J; Tang BL; Song KD; Zhang XH; Zhu XY; Yao W; Wan X; Liu HL; Sun ZM Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):294-300. PubMed ID: 31104440 [No Abstract] [Full Text] [Related]
9. Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation. Truscott L; Pariury H; Hanmod S; Davini M; de la Maza M; Sapp LN; Staples K; Proytcheva M; Katsanis E Pediatr Blood Cancer; 2023 Feb; 70(2):e30102. PubMed ID: 36394072 [TBL] [Abstract][Full Text] [Related]
10. Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients. Cho BS; Yahng SA; Min GJ; Park S; Park SS; Shin SH; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ Transplant Cell Ther; 2021 Sep; 27(9):774.e1-774.e12. PubMed ID: 34082159 [TBL] [Abstract][Full Text] [Related]
11. Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Gorin NC; Labopin M; Blaise D; de Groot M; Socié G; Bourhis JH; Ciceri F; Polge E; Nagler A; Mohty M Cancer; 2020 Mar; 126(5):1004-1015. PubMed ID: 31774557 [TBL] [Abstract][Full Text] [Related]
12. [HLA-10/10 matched unrelated donor versus sibling donor hematopoietic stem cell transplantation for adult acute myeloid leukemia]. Yao JF; Zhang GX; Shen YY; Zhang RL; He Y; Wei JL; Jiang EL; Yang DL; Feng SZ; Han MZ Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):460-466. PubMed ID: 31340617 [No Abstract] [Full Text] [Related]
13. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome. Nakaya Y; Koh H; Konuma T; Shimomura Y; Ishiyama K; Itonaga H; Hino M; Doki N; Nishida T; Ohigashi H; Matsuoka KI; Kanda Y; Maruyama Y; Sawa M; Eto T; Hiramoto N; Fukuda T; Atsuta Y; Nakamae H Transplant Cell Ther; 2024 Mar; 30(3):316.e1-316.e12. PubMed ID: 38108263 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Large Single-Center Analysis. Kim HT; Ho VT; Nikiforow S; Cutler C; Koreth J; Shapiro RM; Gooptu M; Romee R; Wu CJ; Antin JH; Ritz J; Soiffer RJ Transplant Cell Ther; 2024 Jul; 30(7):687.e1-687.e13. PubMed ID: 38703824 [TBL] [Abstract][Full Text] [Related]
15. Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS. Marcoux C; Marin D; Ramdial J; AlAtrash G; Alousi AM; Oran B; Kebriaei P; Popat UR; Rezvani K; Champlin RE; Shpall EJ; Mehta RS Am J Hematol; 2023 May; 98(5):712-719. PubMed ID: 36734029 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status. Konuma T; Yamasaki S; Ishiyama K; Mizuno S; Hayashi H; Uchida N; Shimabukuro M; Tanaka M; Kuriyama T; Onizuka M; Ishiwata K; Sawa M; Tanaka T; Ohigashi H; Fujiwara SI; Matsuoka KI; Ota S; Nishida T; Kanda Y; Fukuda T; Atsuta Y; Nakasone H; Yanada M; Transplant Cell Ther; 2024 Feb; 30(2):215.e1-215.e18. PubMed ID: 38081415 [TBL] [Abstract][Full Text] [Related]
17. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Tsai SB; Rhodes J; Liu H; Shore T; Bishop M; Cushing MM; Gergis U; Godley L; Kline J; Larson RA; Mayer S; Odenike O; Stock W; Wickrema A; van Besien K; Artz AS Biol Blood Marrow Transplant; 2018 May; 24(5):997-1004. PubMed ID: 29288821 [TBL] [Abstract][Full Text] [Related]
18. HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison. Devillier R; Legrand F; Rey J; Castagna L; Fürst S; Granata A; Charbonnier A; Harbi S; d'Incan E; Pagliardini T; Faucher C; Lemarie C; Saillard C; Calmels B; Mohty B; Maisano V; Weiller PJ; Chabannon C; Vey N; Blaise D Biol Blood Marrow Transplant; 2018 Jul; 24(7):1449-1454. PubMed ID: 29448057 [TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. Bashey ZA; Zhang X; Brown S; Jackson K; Morris LE; Holland HK; Bashey A; Solomon SR; Solh M Bone Marrow Transplant; 2018 Jun; 53(6):756-763. PubMed ID: 29523888 [TBL] [Abstract][Full Text] [Related]
20. Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study. Al Hamed R; Ngoya M; Galimard JE; Sengeloev H; Gedde-Dahl T; Kulagin A; Platzbecker U; Yakoub-Agha I; Byrne JL; Valerius T; Socie G; Kröger N; Blaise D; Bazarbachi A; Sanz J; Ciceri F; Nagler A; Mohty M Cancer; 2023 Sep; 129(17):2645-2654. PubMed ID: 37269074 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]